Chemotherapy-induced peripheral neuropathy (CIPN) is one of the most frequent side
effects caused by antineoplastic agents, with a prevalence from 19% to over 85%. Clinically …

Peripheral neuropathies are characterized by nerves damage and axonal loss, and they
could be classified in hereditary or acquired forms. Acquired peripheral neuropathies are …

Background Despite the increasing knowledge of the etiology of neuropathic pain, this type
of chronic pain is resistant to available analgesics in approximately 50% of patients and …

Oxaliplatin (OHP)-induced peripheral neurotoxicity (OIPN) is a severe clinical problem and
potentially permanent side effect of cancer treatment. For the management of OIPN, accurate …

Peripheral neuropathy is a common neurological issue that leads to sensory and motor
disorders. Over time, the treatment for peripheral neuropathy has primarily focused on …

Chemotherapy-induced peripheral neuropathy (CIPN) is an adverse effect caused by
several classes of widely used anticancer therapeutics. Chemotherapy-induced peripheral …

Chemotherapy-induced peripheral neuropathy (CIPN) is a common and dose-limiting
toxicity, negatively affecting both quality of life and disease outcomes. To date, there is no …

The burdensome condition of chemotherapy-induced peripheral neuropathy occurs with
various chemotherapeutics, including bortezomib, oxaliplatin, paclitaxel and vincristine. The …

Improvements in screening, diagnosis and treatment of cancer has seen cancer mortality
substantially diminish in the past three decades. It is estimated there are almost 20 million …

One of the most relevant dose-limiting adverse effects of platinum drugs is the development
of a sensory peripheral neuropathy that highly impairs the patients' quality of life. Nowadays …